Company / SG&A Expense
Bio-Techne SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$588.5M
FY2025
5-year range
$260.6M / $588.5M
FY2021-FY2025
Trend
+26.2%
vs FY2024
Sector context
#63 of 158
Health Care
What the data says
At $589M, Bio-Techne's sg&a expense ranks #96 of 158 in the Health Care sector. SG&A Expense has increased for 3 consecutive years, from $261M in FY2022 to $589M in FY2025.
Based on SEC 10-K filings.
$589M in FY2025 with a 5-year CAGR of +17.7%.
Increased from $325M to $589M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +31.2%
- 5-Year CAGR
- +17.7%
- 10-Year CAGR
- -
Sector benchmark
#96 of 158 in Health CareTop 60% of 158This company $588.5M Sector average $175.9B
▼
-99.7% below sector average
Key checks
Key Insights
- Bio-Techne's sg&a expense has grown for 3 consecutive years.
- 5-year CAGR of +17.7%, indicating consistent growth.
- In FY2025, sg&a expense increased 26.2% year-over-year.
- Ranks #63 out of 158 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $588.5M | +26.2% |
| FY2024 | $466.4M | +43.5% |
| FY2023 | $325.0M | +24.7% |
| FY2022 | $260.6M | -1.4% |
| FY2021 | $264.4M | +1.4% |
| FY2020 | $260.6M | -1.4% |
| FY2019 | $264.4M | +9.9% |
| FY2018 | $240.6M | +20.1% |
| FY2017 | $200.4M | +42.3% |
| FY2016 | $140.9M | +18.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026